Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists ... target peak concentrations or a rapid onset of action. Studies in patients with type 2 diabetes ...

The effects of various agents targeting these gastrointestinal peptide systems ... about the lack of specificity of vildagliptin's action, no notable safety issues emerged in this or other ...

Five researchers have been jointly awarded one of this year's Breakthrough Prizes in Life Sciences for their contributions to the development of Ozempic-style drugs.

Ascletis's news arrives shortly after Eli Lilly reported favourable Phase III weight loss data for its oral GLP-1RA, ...

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is ...

Glucagon-like peptide-1 is a hormone that naturally occurs in the body ... a synthetic version of the hormone more resistant to degradation. By mimicking the action of natural GLP-1, these injections ...

which specifically binds to the co-activator binding site of FXR, thereby blocking co-activator recruitment, reducing intestinal ceramide production, and promoting glucagon-like peptide-1 (GLP-1 ...

investigating the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide on the total cardiovascular (CV) events in patients with CV disease (CVD) who are either overweight or ...

Creatine peptides help boost muscle growth or muscle repair. BPC-157 is said to help joint recovery. Glucagon-like Peptide-1 (GLP-1) is utilized in the treatment of type 2 diabetes and obesity ...